This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Abstract
Objective: We assessed a blood-based signature, which previously demonstrated high accuracy at stratifying individuals with high or low neocortical β-amyloid burden (NAB), to determine whether it could also identify individuals at risk of progression to Alzheimer disease (AD) within 54 months.
Methods: We generated the blood-based signature for 585 healthy controls (HCs) and 74 participants with mild cognitive impairment (MCI) from the Australian Imaging, Biomarkers and Lifestyle Study who underwent clinical reclassification (blinded to biomarker findings) at 54-month follow-up. The individuals were split into estimated high and low NAB groups based on a cutoff of 1.5 standardized uptake value ratio. We assessed the predictive accuracy of the high and low NAB groupings based on progression to mild cognitive impairment or AD according to clinical reclassification at 54-month follow-up.
Results: Twelve percent of HCs with estimated high NAB progressed in comparison to 5% of HCs with estimated low NAB (odds ratio = 2.4). Forty percent of the participants with MCI who had estimated high NAB progressed in comparison to 5% of the participants with MCI who had estimated low NAB (odds ratio = 12.3). These ratios are in line with those reported for Pittsburgh compound B–PET results. Individuals with estimated high NAB had faster rates of memory decline than those with estimated low NAB.
Conclusion: These findings suggest that a simple blood-based signature not only provides estimates of NAB but also predicts cognitive decline and disease progression, identifying individuals at risk of progressing toward AD at the prodromal and preclinical stages.
GLOSSARY
- Aβ=
- β-amyloid;
- AD=
- Alzheimer disease;
- AIBL=
- Australian Imaging, Biomarker and Lifestyle;
- ANOVA=
- analysis of variance;
- AUC=
- area under the curve;
- BBE=
- blood-based estimate;
- BeCKeT=
- Before the Centiloid Kernel Transformation;
- CDR=
- Clinical Dementia Rating;
- CI=
- confidence interval;
- CoxPH=
- Cox proportional hazards;
- CXCL-13=
- chemokine ligand 13;
- FBP=
- 18F-florbetapir;
- FLUTE=
- 18F-flutemetamol;
- HC=
- healthy control;
- IgM-1=
- immunoglobulin M-1;
- IL-17=
- interleukin 17;
- MCI=
- mild cognitive impairment;
- NAB=
- neocortical β-amyloid burden;
- OR=
- odds ratio;
- PiB=
- Pittsburgh compound B;
- PPY=
- pancreatic polypeptide;
- ROC=
- receiver operating characteristic;
- SUV=
- standardized uptake value;
- SUVR=
- standardized uptake value ratio;
- VCAM-1=
- vascular cell adhesion molecule 1
Footnotes
Go to Neurology.org for full disclosures. Funding information and disclosures deemed relevant by the authors, if any, are provided at the end of the article.
Supplemental data at Neurology.org
- Received January 17, 2016.
- Accepted in final form June 1, 2016.
- © 2016 American Academy of Neurology
AAN Members: Sign in with your AAN member credentials (e-mail or 6-digit Member ID number)
Non-AAN Member subscribers: Sign in with subscriber credentials
Log in using your username and password
Purchase access
Disputes & Debates: Rapid online correspondence
NOTE: All authors' disclosures must be entered and current in our database before comments can be posted. Enter and update disclosures at http://submit.neurology.org. Exception: replies to comments concerning an article you originally authored do not require updated disclosures.
- Stay timely. Submit only on articles published within the last 8 weeks.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- 200 words maximum.
- 5 references maximum. Reference 1 must be the article on which you are commenting.
- 5 authors maximum. Exception: replies can include all original authors of the article.
- Submitted comments are subject to editing and editor review prior to posting.